FDA WARNING_LETTER - Amazon.com, Inc. - August 09, 2022
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
The FDA issued a Warning Letter to Amazon on August 4, 2022, regarding the distribution of unapproved new drugs on www.amazon.com. The FDA purchased "Deisana Skin Tag Remover, Mole Remover and Repair Gel Set" and "Skincell Mole Skin Tag Corrector Serum" through Amazon's website, which were then distributed via Amazon's Fulfillment by Amazon service.
These products are classified as "drugs" under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), due to their intended use for mole and skin tag removal, which affects the body's structure or function. The FDA states there are no legally sold over-the-counter (OTC) drugs for mole or skin tag removal, and has safety concerns, including potential delayed cancer diagnosis and scarring.
The products are considered "new drugs" under section 201(p) of the FD&C Act, 21 U.S.C. 321(p), as they are not generally recognized as safe and effective for their intended uses. Introducing or delivering these unapproved new drugs into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(
ID · 15ec5b0d-f792-4899-a54f-6f4d96d6b86f
Full citation text and observation details available on the Dashboard.